Nkarta Expects Initial Data From CAR NK Cell Therapy In Blood Cancer In 2022
Magenta Therapeutics' Shares Gain As FDA Signs Off Blood Cancer Candidate To Enter Human Trial
INmune Bio Stock Jumps On Promising Biomarker Data From Early-Stage Blood Cancer Trial
Aprea Therapeutics Stock Drops After FDA Clinical Hold On Another Blood Cancer Study